Literature DB >> 22539583

Telomere abnormalities and chromosome fragility in patients affected by familial papillary thyroid cancer.

Silvia Cantara1, Milena Pisu, Daniela Virginia Frau, Paola Caria, Tinuccia Dettori, Marco Capezzone, Serena Capuano, Roberta Vanni, Furio Pacini.   

Abstract

INTRODUCTION: Genomic instability has been proposed to play a role in cancer development and can occur through different mechanisms including telomere association and telomere loss. Studies carried out in our unit have demonstrated that familial papillary thyroid cancer (fPTC) patients display an imbalance, at the germinal level, in telomere-telomerase complex. AIM: We aimed to verify whether familial fPTC patients show an increased spontaneous chromosome fragility.
METHODS: To this purpose, we compared telomeric fusions and associations as well as other chromosomal fragility features by conventional and molecular cytogenetic analyses, in phytohemagglutinin stimulated T-lymphocytes from fPTC patients, unaffected family members, sporadic papillary thyroid cancer patients, and healthy subjects.
RESULTS: We demonstrate that fPTC patients have a significant increase in spontaneous telomeric associations and telomeric fusions compared with healthy subjects and sporadic cases in the frame of an otherwise common spontaneous chromosome fragility pattern. A quantitative fluorescence in situ hybridization analysis demonstrates that familial cases display a significant decrease in the telomeric peptide nucleic acid-fluorescence in situ hybridization signal intensity in the metaphase chromosome. Moreover, three copies of the hTERT gene were found only in familial cases, although the result was not statistically significant.
CONCLUSIONS: These results contribute in defining familial thyroid cancer as a clinical entity characterized by an altered telomere stability, which may be associated with the predisposition to develop the familial form of thyroid cancer.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22539583     DOI: 10.1210/jc.2011-2096

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  12 in total

Review 1.  Controversies in familial thyroid cancer 2014.

Authors:  Orlo H Clark
Journal:  Ulus Cerrahi Derg       Date:  2014-06-01

Review 2.  TERT Promoter Mutations in Thyroid Cancer.

Authors:  Ali S Alzahrani; Rawan Alsaadi; Avaniyapuram Kannan Murugan; Bakr Bin Sadiq
Journal:  Horm Cancer       Date:  2016-02-22       Impact factor: 3.869

3.  HABP2 G534E variation in familial non-medullary thyroid cancer: an Italian series.

Authors:  S Cantara; C Marzocchi; M G Castagna; F Pacini
Journal:  J Endocrinol Invest       Date:  2016-11-21       Impact factor: 4.256

Review 4.  Telomerase promoter mutations in cancer: an emerging molecular biomarker?

Authors:  João Vinagre; Vasco Pinto; Ricardo Celestino; Marta Reis; Helena Pópulo; Paula Boaventura; Miguel Melo; Telmo Catarino; Jorge Lima; José Manuel Lopes; Valdemar Máximo; Manuel Sobrinho-Simões; Paula Soares
Journal:  Virchows Arch       Date:  2014-07-22       Impact factor: 4.064

5.  Telomere attrition and inflammatory load in severe psychiatric disorders and in response to psychotropic medications.

Authors:  Alessio Squassina; Mirko Manchia; Claudia Pisanu; Raffaella Ardau; Carlo Arzedi; Alberto Bocchetta; Paola Caria; Cristina Cocco; Donatella Congiu; Eleonora Cossu; Tinuccia Dettori; Daniela Virginia Frau; Mario Garzilli; Elias Manca; Anna Meloni; Maria Antonietta Montis; Andrea Mura; Mariella Nieddu; Barbara Noli; Pasquale Paribello; Federica Pinna; Renato Robledo; Giovanni Severino; Valeria Sogos; Maria Del Zompo; Gian Luca Ferri; Caterina Chillotti; Roberta Vanni; Bernardo Carpiniello
Journal:  Neuropsychopharmacology       Date:  2020-09-12       Impact factor: 7.853

6.  Telomere content and risk of second malignant neoplasm in survivors of childhood cancer: a report from the Childhood Cancer Survivor Study.

Authors:  Maria M Gramatges; Qi Liu; Yutaka Yasui; M Fatih Okcu; Joseph P Neglia; Louise C Strong; Gregory T Armstrong; Leslie L Robison; Smita Bhatia
Journal:  Clin Cancer Res       Date:  2013-11-25       Impact factor: 12.531

7.  Expression of Spindle and Kinetochore-Associated Protein 1 Is Associated with Poor Prognosis in Papillary Thyroid Carcinoma.

Authors:  Chao Dong; Xiao-li Wang; Bin-lin Ma
Journal:  Dis Markers       Date:  2015-05-04       Impact factor: 3.434

8.  Genetic Heterogeneity of HER2 Amplification and Telomere Shortening in Papillary Thyroid Carcinoma.

Authors:  Paola Caria; Silvia Cantara; Daniela Virginia Frau; Furio Pacini; Roberta Vanni; Tinuccia Dettori
Journal:  Int J Mol Sci       Date:  2016-10-21       Impact factor: 5.923

9.  Familial multinodular goiter syndrome with papillary thyroid carcinomas: mutational analysis of the associated genes in 5 cases from 1 Chinese family.

Authors:  Shunyao Liao; Wenzhong Song; Yunqiang Liu; Shaoping Deng; Yaming Liang; Zhenlin Tang; Jiyuan Huang; Dandan Dong; Gang Xu
Journal:  BMC Endocr Disord       Date:  2013-10-21       Impact factor: 2.763

10.  TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas.

Authors:  Miguel Melo; Adriana Gaspar da Rocha; João Vinagre; Rui Batista; Joana Peixoto; Catarina Tavares; Ricardo Celestino; Ana Almeida; Catarina Salgado; Catarina Eloy; Patrícia Castro; Hugo Prazeres; Jorge Lima; Teresina Amaro; Cláudia Lobo; Maria João Martins; Margarida Moura; Branca Cavaco; Valeriano Leite; José Manuel Cameselle-Teijeiro; Francisco Carrilho; Manuela Carvalheiro; Valdemar Máximo; Manuel Sobrinho-Simões; Paula Soares
Journal:  J Clin Endocrinol Metab       Date:  2014-01-29       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.